Clinical Trial Update: Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing nivolumab plus S-1 and oxaliplatin vs nivolumab alone as neoadjuvant therapy for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• nivolumab (nivolumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Gastric Cancer, Chemotherapy Effect | Phase 2 | Status: UNKNOWN